171 related articles for article (PubMed ID: 37082801)
1. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
Hacking SM; Yakirevich E; Wang Y
J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast.
Seijnhaeve E; Galant C; Van Bockstal MR
Int J Surg Pathol; 2021 Aug; 29(5):496-502. PubMed ID: 33426999
[TBL] [Abstract][Full Text] [Related]
3. Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
Bean GR; Najjar S; Shin SJ; Hosfield EM; Caswell-Jin JL; Urisman A; Jones KD; Chen YY; Krings G
Mod Pathol; 2022 Oct; 35(10):1349-1361. PubMed ID: 35590107
[TBL] [Abstract][Full Text] [Related]
4. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.
Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E
Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220
[TBL] [Abstract][Full Text] [Related]
5. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
6. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
7. Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features.
Turkevi-Nagy S; Báthori Á; Böcz J; Krenács L; Cserni G; Kővári B
Pathol Oncol Res; 2021; 27():1610039. PubMed ID: 34764822
[No Abstract] [Full Text] [Related]
8. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.
Subhawong AP; Subhawong T; Nassar H; Kouprina N; Begum S; Vang R; Westra WH; Argani P
Am J Surg Pathol; 2009 Feb; 33(2):163-75. PubMed ID: 18936692
[TBL] [Abstract][Full Text] [Related]
9. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
[TBL] [Abstract][Full Text] [Related]
10. Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: application and future prospective.
Kawasaki T; Kaira K
Virchows Arch; 2021 Jul; 479(1):191-194. PubMed ID: 33025295
[TBL] [Abstract][Full Text] [Related]
11. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
12. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections.
Mukhopadhyay S; Dermawan JK; Lanigan CP; Farver CF
Mod Pathol; 2019 Jan; 32(1):100-109. PubMed ID: 30154579
[TBL] [Abstract][Full Text] [Related]
13. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
[TBL] [Abstract][Full Text] [Related]
14. INSM1 immunostaining in solid papillary carcinoma of the breast.
Kudo N; Takano J; Kudoh S; Arima N; Ito T
Pathol Int; 2021 Jan; 71(1):51-59. PubMed ID: 33156579
[TBL] [Abstract][Full Text] [Related]
15. Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors.
Möller K; Uhlig R; Gorbokon N; Dum D; Menz A; Büscheck F; Luebke AM; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Lebok P; Weidemann S; Lennartz M; Jacobsen F; Clauditz TS; Steurer S; Burandt E; Krech R; Krech T; Marx AH; Sauter G; Simon R; Bernreuther C; Minner S
Mol Cell Endocrinol; 2024 Feb; 581():112106. PubMed ID: 37951531
[TBL] [Abstract][Full Text] [Related]
16. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.
Chen JF; Yang C; Sun Y; Cao D
Pathol Res Pract; 2020 Jun; 216(6):152993. PubMed ID: 32381384
[TBL] [Abstract][Full Text] [Related]
17. INSM1 Expression in Breast Neoplasms with Neuroedocrine Features.
Metovic J; Castellano I; Marinelli E; Osella-Abate S; Sapino A; Cassoni P; Papotti M
Endocr Pathol; 2021 Dec; 32(4):452-460. PubMed ID: 34008122
[TBL] [Abstract][Full Text] [Related]
18. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
20. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
Tan HL; Sood A; Rahimi HA; Wang W; Gupta N; Hicks J; Mosier S; Gocke CD; Epstein JI; Netto GJ; Liu W; Isaacs WB; De Marzo AM; Lotan TL
Clin Cancer Res; 2014 Feb; 20(4):890-903. PubMed ID: 24323898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
